IDEAS home Printed from https://ideas.repec.org/a/spr/pharme/v25y2007i11p913-933.html
   My bibliography  Save this article

The Cost Effectiveness of Bisphosphonates for the Prevention and Treatment of Osteoporosis

Author

Listed:
  • Rachael Fleurence
  • Cynthia Iglesias
  • Jeanene Johnson

Abstract

Osteoporotic fragility fractures constitute a significant public health concern. The lifetime risk of any osteoporotic fracture is very high (40–50% in women and 13–22% in men). Fractures are associated with significant mortality and morbidity and represent a substantial economic burden to society. Bisphosphonates (alendronate, etidronate, risedronate and ibandronate) are indicated for the treatment and prevention of osteoporosis but are costly compared with other treatments, such as vitamin D and calcium. Our search identified 23 studies evaluating the cost effectiveness of bisphosphonate therapy for the treatment and prevention of fragility fractures; these studies were from five geographical areas and employed a variety of comparators and assumptions. We identified 11 studies investigating bisphosphonates in women with low bone mineral density (BMD) [T-score >2.5 standard deviations {SDs} below normal {mean} peak values for young adults] and previous fractures, five studies investigating bisphosphonates in women with low BMD and no previous fracture, one study of bisphosphonates in women with osteopenia, five studies involving screening and two studies of bisphosphonates in special populations (women initiating corticosteroid treatment and men). In women with low BMD and previous fractures, bisphosphonate therapy was most cost effective in populations aged ≥70 years and was unlikely to be cost effective in populations aged ≤50 years. There was uncertainty concerning the cost effectiveness of bisphosphonates in such populations aged 60–69 years. In women with low BMD without previous fractures, treatment with alendronate or risedronate appeared to be cost effective across countries (UK, US, Denmark), but there was some uncertainty about the cost effectiveness of etidronate in patients in the highest age groups. Identifying risk factors for fractures through means such as spine radiographs to detect vertebral deformities improves the cost effectiveness of treatment. In women with osteopenia, alendronate therapy may be cost effective in women with a T-score of -2.4SD in the US. Screening for low BMD and treatment with alendronate or etidronate appears to be cost effective in postmenopausal women in general and in women with rheumatoid arthritis initiating corticosteroid therapy. Alendronate therapy without screening was also shown to be potentially cost effective in certain at-risk male populations, as well as in women initiating corticosteroid therapy after the age of 40 years. Decision makers in the US, UK and Sweden should consider funding the use of bisphosphonates for the prevention and treatment of osteoporosis in women aged >70 years, particularly if they have other risk factors for fracture. Further studies are required to make more definitive conclusions in other countries and patient populations. Screening strategies for low BMD followed by bisphosphonate treatment should also be considered in the general female population aged >65 years in the UK and US and in patients with rheumatoid arthritis initiating corticosteroid therapy. Copyright Adis Data Information BV 2007

Suggested Citation

  • Rachael Fleurence & Cynthia Iglesias & Jeanene Johnson, 2007. "The Cost Effectiveness of Bisphosphonates for the Prevention and Treatment of Osteoporosis," PharmacoEconomics, Springer, vol. 25(11), pages 913-933, November.
  • Handle: RePEc:spr:pharme:v:25:y:2007:i:11:p:913-933
    DOI: 10.2165/00019053-200725110-00003
    as

    Download full text from publisher

    File URL: http://hdl.handle.net/10.2165/00019053-200725110-00003
    Download Restriction: Access to full text is restricted to subscribers.

    File URL: https://libkey.io/10.2165/00019053-200725110-00003?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Lee R. Mobley & Thomas J. Hoerger & John S. Wittenborn & Deborah A. Galuska & Jaya K. Rao, 2006. "Cost-Effectiveness of Osteoporosis Screening and Treatment with Hormone Replacement Therapy, Raloxifene, or Alendronate," Medical Decision Making, , vol. 26(2), pages 194-206, March.
    2. Hege Urdahl & Andrea Manca & Mark Sculpher, 2006. "Assessing Generalisability in Model-Based Economic Evaluation Studies," PharmacoEconomics, Springer, vol. 24(12), pages 1181-1197, December.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Smita Nayak & Mark S Roberts & Susan L Greenspan, 2012. "Impact of Generic Alendronate Cost on the Cost-Effectiveness of Osteoporosis Screening and Treatment," PLOS ONE, Public Library of Science, vol. 7(3), pages 1-7, March.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. F. El Masri & E. Sapin de Brosses & K. Rhissassi & W. Skalli & D. Mitton, 2012. "Apparent Young's modulus of vertebral cortico-cancellous bone specimens," Computer Methods in Biomechanics and Biomedical Engineering, Taylor & Francis Journals, vol. 15(1), pages 23-28.
    2. Katharina Korber, 2014. "Potential Transferability of Economic Evaluations of Programs Encouraging Physical Activity in Children and Adolescents across Different Countries—A Systematic Review of the Literature," IJERPH, MDPI, vol. 11(10), pages 1-16, October.
    3. Smita Nayak & Mark S Roberts & Susan L Greenspan, 2012. "Impact of Generic Alendronate Cost on the Cost-Effectiveness of Osteoporosis Screening and Treatment," PLOS ONE, Public Library of Science, vol. 7(3), pages 1-7, March.
    4. Björn Stollenwerk & Afschin Gandjour & Markus Lüngen & Uwe Siebert, 2013. "Accounting for increased non-target-disease-specific mortality in decision-analytic screening models for economic evaluation," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(6), pages 1035-1048, December.
    5. Dirk Mueller & Afschin Gandjour, 2011. "Cost effectiveness of secondary vs tertiary prevention for post-menopausal osteoporosis," Applied Health Economics and Health Policy, Springer, vol. 9(4), pages 259-273, July.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharme:v:25:y:2007:i:11:p:913-933. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.